Abnormal uptake of Tc-99m MIBI, a novel myocardial imaging agent, in the lungs of patients with systemic sclerosis

Clinical Nuclear Medicine

Volumn 23, Issue 1, 1998, Pages 19-25

  Richard, Michael ^a   Cox, Darrin ^a   Earle, Linda ^a   Varga, John ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Imaging; MIBI; Pulmonary Fibrosis; Systemic Sclerosis

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTRAVENOUS DRUG ADMINISTRATION; LUNG PARENCHYMA; LUNG SCINTISCANNING; MALE; PHASE 2 CLINICAL TRIAL; RADIOISOTOPE DISTRIBUTION; SYSTEMIC SCLEROSIS; TISSUE DISTRIBUTION;

CORONARY DISEASE; DYSPNEA; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; HEART; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MITOCHONDRIA; PILOT PROJECTS; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RADIOPHARMACEUTICALS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 0031938893     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199801000-00007     Document Type: Article

References (27)

1. Altman RD, Medsger TA Jr, Block DA, Michel BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403, 1991.
2. Black CM, duBois RM: Organ involvement: Pulmonary. In: Systemic Sclerosis. Clements PJ and Furst D (eds.) Baltimore: Williams & Wilkins, 1996; pp 299-333.
3. 67Gallium lung scans in progressive systemic sclerosis. Arthritis Rheum 26:969, 1983.
4. Furst DE, Davis JA, Clements PJ, Chopra SK, Theofilopoulos AN, Chia D: Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum 24:1403, 1981.
5. Kramer EL, Divgi CR: Pulmonary application of nuclear medicine. Chest Med 12:55, 1991.
6. 99mTc- DTPA clearance. Respir Med 83:403, 1989.
7. Fanti S, De Fabritiis A, Sloisi D, et al: Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med 35:1933, 1994.
8. Wackers FJ-Th, Berman DS, Maddahi J, Beller G, Strauss H, Bouchet C: Technetium-99-m-hexakis-2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30:301, 1989.
9. Savi A, Gerundino P, Zoli P, et al: Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. Eur J Nucl Med 15:597, 1989.
10. Calelwell JH, Mertens H, Linssen MCJG, van der Vusse GJ, Buell U, Kammermeier H: Uptake kinetics of technetium-99m-methoxyisobutylisonitrile and thallium-201 in adult rat heart endothelial and fibroblast-like cells in comparison to myocytes. J Nucl Med 33:102, 1993.
11. Piwnica-Worms D, Kornauge JF, Holman BL, et al: Hexakis (carboxymethoxyliso-propyl-isonitrile) technetium(I), a new myocardial perfusion imaging agent: binding characteristics in cultured chick heart cells. J Nucl Med 29:55, 1988.
12. Delmon-Moinegan LI, Piwnica-Worms D, Van den Abbeele AD, et: al: Uptake of the cation hexakis (2-methoxyisobutyl isoni- trile) technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50:2198, 1990.
13. Chiu ML, Kronauge JF, Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 31:1646, 1990.
14. Piwnica-Worms D, Holman BL: Noncardiac applications of hexakis-(alkylnitrile) technetium-99m complexes. J Nucl Med 31:1166, 1990.
15. Richard MD, Park CH: Technetium 99m MIBI uptake secondary to pulmonary interstitial fibrosis in progressive systemic sclerosis. Clin Nucl Med 20:256, 1995.
16. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581, 1980.
17. LeRoy EC, Black CM, Fleishmajer R, et al: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202, 1988.
18. Varga J, Haustein UF, Creech RH, Dwyer FP, Jimenez SA: Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 265:3292, 1991.
19. Cox D, Earle L, Jimenez SA, Lieferman KM, Gleich GJ, Varga J: Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. Arthritis Rheum 38:939, 1995.
20. Morris AH, Karner RE, Crapo RO, et al: Clinical pulmonary function testing. In: A Manual of Uniform Laboratory Procedures, 2nd Ed. Intermountain Thoracic Society, 1984.
21. Wechsler RJ, Steiner RM, Spirn PW, et al: Limited and diffuse systemic sclerosis: the relationship of mediastinal lymphadenopathy and pulmonary interstitial disease. Am J Roentgenol 167:101, 1996.
22. Briggs DC, Vaughen RW, Welsh KI, Myers A, du Bois RM, Black CM: Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 338:661, 1991.
23. Gauldie J, Jordana M, Cox G: Cytokines and pulmonary fibrosis. Thorax 48:931, 1993.
24. Corrin B, Butcher D, McAnulty RJ, et al: Immunohistochemical localization of transforming growth factor beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 24:145, 1994.
25. Deguchi Y: Spontaneous increase of transforming growth factor beta production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung. Ann Rheum Dis 51:362, 1992.
26. Bajnok L, Kozlovszky B, Varga J, et al: Technetium-99m sestamibi seintigraphy for the assessment of lower extremity ischaemia in peripheral arterial disease. Eur J Nucl Med 21:1326, 1994.
27. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez SA, Fish JE: Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Resp Med 90:223, 1996.